IARC Monographs Volume 100B
Human Papillomaviruses

Supplementary Web Tables, Section 2, Cancer in Humans

  These web tables formed part of the original submission and have been peer reviewed. They
  are posted as supplied by the Working Group. Readers are requested to report any errors to:
  edit-vol100B@iarc.fr.
Table 2.2   HPV genotypes in cytologically normal women and those with low-grade cytological or
                    histological lesions
Table 2.3   Rates of detection of type-specific HPV DNA or RNA among women with invasive cervical
                    cancer, restricted to studies with approximately 50 cases or more of cancer
Table 2.4   Rates of detection of type-specific HPV DNA or RNA among women with CIN3
Table 2.6   Prevalence of HPV DNA in grade 3 vulvar intraepithelial neoplasia (VIN3) (9 cases)
Table 2.7   Prevalence of HPV DNA in case series of vulvar cancer (10 cases)
Table 2.8   Case–control studies of HPV and VIN II/III or ISC cancer
Table 2.9   Case–control studies of HPV and vulvar cancer
Table 2.10 Prevalence of HPV DNA in case series of grade 3 vaginal intraepithelial neoplasia (VAIN3)
                    (>3 cases)
Table 2.11 Prevalence of HPV DNA in case-series of vaginal cancer
Table 2.12 Case-control studies of HPV and grade 3 vaginal intraepithelial neoplasia (VaIN3)
Table 2.13 Case–control studies of HPV and vaginal cancer
Table 2.14 Prevalence of HPV DNA in case series of penile cancer and penile intraepithelial neoplasia
Table 2.15 Case–control studies of HPV and penile cancer and penile intraepithelial neoplasia
Table 2.16 Prevalence of HPV DNA in case series of AIN
Table 2.17 Prevalence of HPV DNA in case series of anal cancer
Table 2.18 Case-control studies of HPV AIN prevalence
Table 2.19 Case–control studies of HPV prevalence and anal cancer
Table 2.20 Prevalence of HPV DNA in case series of cancers of the oral cavity (>40 cases) detected by
                    the polymerase chain reaction (PCR) method
Table 2.21 Case–control studies of HPV prevalence and cancers of the oral cavity
Table 2.22 Prevalence of HPV DNA in case series of cancers of the oropharynx and tonsil, detected by
                    the polymerase chain reaction method (PCR)
Table 2.23 Case–control studies of HPV prevalence and cancers of the oropharynx and tonsil
Table 2.24 Prevalence of HPV DNA in case series of cancers of the oesophagus detected by PCR
Table 2.25 Case–control studies of HPV prevalence and oesophageal cancer
Table 2.26 Prevalence of HPV DNA in case series of laryngeal cancer detected by PCR
Table 2.27 Studies of HPV and skin cancer
Table 2.28 Prevalence of HPV DNA in case series of lung cancer detected by PCR
Table 2.29 Prevalence of HPV DNA in case series of cancers of the prostate detected by PCR
Table 2.30 Case–control studies of HPV prevalence and cancer of the prostate
Table 2.31 Prevalence of HPV DNA in case series of cancers of the urinary bladder